The a2 Milk Company has cleared the last regulatory hurdle standing between its Pokeno factory and the Chinese infant formula market, and it is handing shareholders a $300 million reward for the wait. The dual-listed dairy company told the market this week that China’s State Administration for Market Regulation had approved the transition of two China label infant formula registrations to the a2 brand, allowing product made at the Waikato plant to be sold into China under the company’s own label later this year.
The approval matters because China is the single most important market for a2 Milk and its English and Chinese label infant formula is the engine of the business. Until now the company has leaned almost entirely on a single supplier, Synlait Milk, which makes its formula at Dunsandel in Canterbury. Owning manufacturing at Pokeno gives a2 a second source of supply and far more control over its own future, which is exactly why the company bought the plant from China’s state-linked Yashili late in 2025.
Chief executive and managing director David Bortolussi said the decision was a turning point for the business. The approval “supports long-term growth in our core infant formula business through market access and innovation” and “accelerates the development of advanced nutritional manufacturing capability”, he said in the company’s statement to the exchange. The new products are expected to launch later in 2026, with no change to the financial benefits the company had already flagged.
Investors did not wait to celebrate. The shares jumped 89 cents, or about 11 percent, to $9.00 on the day of the announcement, one of the sharpest single-day moves the stock has seen this year. For a company that spent the back half of the last decade lurching from one China-related shock to another, a clean regulatory win followed by a large cash return is the kind of news long-suffering holders have been waiting for.
The headline number for shareholders is the special dividend. The board intends to declare a fully franked special dividend worth $300 million, which works out at roughly 41 cents a share. It is the first time the company has returned cash to shareholders through a dividend in its history, having spent years hoarding capital to fund its own growth and a long-running share buyback. The payout is scheduled to be made on 24 July, with the shares trading without the entitlement from early in the month.
There is a catch for New Zealand investors worth understanding. The dividend is fully franked, which carries Australian tax credits, but it is unimputed, meaning it does not come with New Zealand imputation credits. For many local shareholders that makes the cash less tax-efficient than a fully imputed New Zealand dividend would be, a quirk that flows from a2’s heavily Australian shareholder base and its dual listing on both the New Zealand and Australian exchanges. Even so, a cash return of this size is a clear signal that the board now sees the Pokeno integration as largely de-risked.
The dividend lands on the back of a strong run of results. In its 2025 financial year the company lifted sales 13.5 percent to $1.9 billion and grew net profit after tax by almost a quarter to $192.1 million. The momentum carried into the current year, with first-half revenue up 18.8 percent to $993.5 million and net profit up 9.4 percent to $112.1 million. That earnings strength, combined with a balance sheet stuffed with cash, is what allows the board to fund both the Pokeno purchase and a large one-off payout at the same time.
For New Zealand the story is bigger than one company’s dividend cheque. a2 Milk is one of the few homegrown consumer brands to have built a genuine premium position in China, and the Pokeno plant adds high-value manufacturing on New Zealand soil rather than shipping the value offshore. Infant formula is among the country’s most valuable dairy exports per kilogram, and a fully owned, China-approved plant in the Waikato strengthens the case that New Zealand can move beyond bulk milk powder into branded, regulated nutritional products that command far higher margins.
It also reshapes the relationship with Synlait, which has been through its own turbulent stretch and counts a2 as both its largest customer and a major shareholder. With Pokeno now able to supply China-bound formula, a2 has options it did not have a year ago, and the balance of power between the two companies has shifted.
Plenty of execution risk remains. Approval to sell is not the same as selling, and the company still has to launch the new products into a Chinese market where the birth rate is falling and competition is fierce. But after years in which a2’s China exposure was treated as a threat, this week it looked a lot more like an asset.
You can read the company’s announcement on the NZX and further coverage at the NZ Herald and elsewhere.
Are you an a2 Milk shareholder, or do you think New Zealand should be doing more to keep high-value food manufacturing onshore? Share your thoughts in the comments below.
This article was written by AI, briefed to report the facts, hopefully without some of the bias people bring to the job π
Leave a Reply